Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Axl-1717. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | TUBB4A | P04350 | 5/20 | 1.00 |
| ▸ | TUBB | P07437 | 5/20 | 1.00 |
| ▸ | TUBA3C | P0DPH7 | 5/20 | 1.00 |
| ▸ | TUBA1B | P68363 | 5/20 | 1.00 |
| ▸ | TUBA4A | P68366 | 5/20 | 1.00 |
| ▸ | TUBB4B | P68371 | 5/20 | 1.00 |
| ▸ | TUBB3 | Q13509 | 5/20 | 1.00 |
| ▸ | TUBB2A | Q13885 | 5/20 | 1.00 |
| ▸ | TUBB8 | Q3ZCM7 | 5/20 | 1.00 |
| ▸ | TUBA3E | Q6PEY2 | 5/20 | 1.00 |
| ▸ | TUBA1A | Q71U36 | 5/20 | 1.00 |
| ▸ | TUBA1C | Q9BQE3 | 5/20 | 1.00 |
| ▸ | TUBB6 | Q9BUF5 | 5/20 | 1.00 |
| ▸ | TUBB2B | Q9BVA1 | 5/20 | 1.00 |
| ▸ | TUBB1 | Q9H4B7 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Podofilox SCHEMBL12377923 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C | |
| Podofilox SCHEMBL30947382 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C | |
| Podofilox SCHEMBL10005569 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C | |
| Podofilox SCHEMBL13663652 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C | |
| Podofilox SCHEMBL10046308 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C | |
| Epipodophyllotoxin SCHEMBL5792464 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C | |
| Podofilox SCHEMBL24049951 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C | |
| Podofilox SCHEMBL42243 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C | |
| Podofilox SCHEMBL13661743 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C | |
| Podofilox SCHEMBL20807187 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 650 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739392-A1 | METHODS OF TREATING ACTIVE AND CHRONIC THYROID EYE DISEASE | Viridian Therapeutics, Inc. (US) | 2026-05-13 | — | — | EP | claimed |
| EP-4363043-B1 | COMPOSITIONS FOR USE IN METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2026-04-22 | — | — | EP | claimed |
| EP-4718511-A1 | SECONDARY BATTERY ELECTRODE, AND SECONDARY BATTERY INCLUDING SAME | SK On Co., Ltd. (KR) | 2026-04-01 | — | — | EP | claimed |
| US-20250325411-A1 | SMART ABSORBENT ARTICLES WITH AUTOMATED STOOL AND URINE DETECTION | ONTEX BV (BE) | 2025-10-23 | — | — | US | claimed |
| EP-3936102-B1 | MONITORING DEVICE ATTACHABLE TO AN ABSORBENT ARTICLE, AND RESPECTIVE METHOD AND ABSORBENT ARTICLE | ONTEX BV (BE) | 2025-10-08 | — | — | EP | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| US-12383437-B2 | Smart absorbent articles | ONTEX BV (BE) | 2025-08-12 | — | — | US | claimed |
| WO-2025137608-A1 | REINFORCED IONOMERIC POLYPHENYLENE MEMBRANES AND METHODS OF USE THEREOF | IONOMR INNOVATIONS INC. (CA) | 2025-06-26 | — | — | WO | claimed |
| EP-4178512-B1 | MANUFACTURING METHOD FOR AN ABSORBENT ARTICLE COMPRISING A POCKET AND ABSORBENT ARTICLE BEING PRODUCIBLE THEREBY | ONTEX BV (BE) | 2025-06-18 | — | — | EP | claimed |
| EP-4561515-A1 | SMART ABSORBENT ARTICLES WITH AUTOMATED STOOL AND URINE DETECTION | Ontex BV (BE) | 2025-06-04 | — | — | EP | claimed |
| EP-4054579-A1 | METHODS FOR THE TREATMENT OF CANCERS THAT HAVE ACQUIRED RESISTANCE TO KINASE INHIBITORS | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2022-09-14 | — | — | EP | claimed |
| US-20220249298-A1 | SMART ABSORBENT ARTICLE, COMPONENTS, AND PROCESS OF MAKING | ONTEX GROUP NV (BE) | 2022-08-11 | — | — | US | claimed |
| US-20220168706-A1 | COMPOSITES FOR EXTRACTION OF METAL OR CONTAMINATING CHEMICAL SPECIES | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2022-06-02 | — | — | US | claimed |
| US-20220143049-A1 | A DBAIT MOLECULE IN COMBINATION WITH KINASE INHIBITOR FOR THE TREATMENT OF CANCER | VALERIO THERAPEUTICS (FR) | 2022-05-12 | — | — | US | claimed |
| EP-3993691-A1 | SUBSTRATE, ABSORBENT ARTICLE AND METHOD FOR WETNESS MONITORING | Ontex BV (BE) | 2022-05-11 | — | — | EP | claimed |
| WO-2022078881-A1 | METHOD FOR MANUFACTURING AN ELECTRODE FOR A LITHIUM-ION BATTERY, AND ELECTRODE MANUFACTURED ACCORDING TO THE METHOD | AIXTRON SE (DE) | 2022-04-21 | — | — | WO | claimed |
| EP-3672721-B1 | USE OF COMPOSITES FOR EXTRACTION OF METAL OR CONTAMINATING CHEMICAL SPECIES | ECOLE POLYTECHNIQUE FED LAUSANNE EPFL (CH) | 2022-04-13 | — | — | EP | claimed |
| EP-3415130-B1 | SMART ABSORBENT ARTICLE, COMPONENTS, AND PROCESS OF MAKING | ONTEX BV (BE) | 2022-04-13 | — | — | EP | claimed |
| US-20220109162-A1 | ELECTRODE INCLUDING METAL NANOPARTICLES HAVING CONDUCTIVE POLYMER SHELL AND CONDUCTIVE FILM AND METHOD FOR MANUFACTURING THE SAME | KIA CORPORATION (KR) | 2022-04-07 | — | — | US | claimed |
| EP-3942045-A1 | A DBAIT MOLECULE IN COMBINATION WITH KINASE INHIBITOR FOR THE TREATMENT OF CANCER | ONXEO (FR) | 2022-01-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220143049-A1 | A DBAIT MOLECULE IN COMBINATION WITH KINASE INHIBITOR FOR THE TREATMENT OF CANCER | MAP3K20, MAP3K10, DCK | LMNA 3420/4885CYP3A4 4419/4885TUBB4A 2037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.